...
首页> 外文期刊>Molecular biology reports >Cloning, expression, purification and spectrophotometric analysis of lanosterol 14-alpha demethylase from Leishmania braziliensis (LbCYP51)
【24h】

Cloning, expression, purification and spectrophotometric analysis of lanosterol 14-alpha demethylase from Leishmania braziliensis (LbCYP51)

机译:Leishmania Braziliensis Lanteroll 14-α脱甲基酶的克隆,表达,纯化和分光光度分析(LBCYP51)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Leishmaniasis, a neglected tropical disease, is a major cause of morbidity and mortality worldwide. Of the three main clinical forms, cutaneous leishmaniasis (CL) is the most common and 40 million people are at risk in the endemic areas. Currently, the available drugs to fight leishmaniasis have high toxicity and poor efficiency. Then, it is very important to search for effective and safe drugs that would target essential enzymes from the parasite, such as lanosterol 14-alpha demethylase (CYP51, EC 1.14.13.70) from Leishmania braziliensis. Because most drug design efforts have been directed for Leishmania non-braziliensis species, there is no structural or kinetic data regarding L. braziliensis CYP51. Herein, we present for the first time molecular biology efforts and purification protocol to obtain the enzyme LbCYP51. These results lay the ground for future investigation of drugs against this target.
机译:Leishmaniaisis是一种被忽视的热带病,是全世界发病率和死亡率的主要原因。 在三种主要的临床形式中,皮肤利什曼病(CL)是最常见的,40万人受到地方性地区的风险。 目前,可用的药物用于对抗LeishManiaisis具有很高的毒性和效率差。 然后,寻找有效和安全的药物是非常重要的,这些药物将来自寄生虫的必需酶,例如来自Leishmania Braziliensis的Lanterol 14-α脱甲基酶(CYP51,EC 1.14.1.70)。 由于大多数药物设计努力都针对Leishmania非巴西物种,因此没有关于L.Braziliensis Cyp51的结构或动力学数据。 在此,我们存在第一次分子生物学努力和纯化方案以获得酶LBCOP51。 这些结果为未来对此目标的药物调查奠定了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号